Strides Pharma Science Ltd

Strides Pharma Science Ltd has demonstrated a notable shift in price momentum, moving from a mildly bullish to a bullish technical trend, supported by strong weekly and monthly MACD indicators and daily moving averages. Despite some bearish signals from monthly RSI and KST, the stock’s recent performance and technical parameters suggest a cautiously optimistic outlook for investors.

The Sensex climbed 2.3% on 12 Jun 2026, yet Strides Pharma Science Ltd outpaced the broader market with a 7.14% gain, reaching an intraday high of Rs 1062.9. This 6.32 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a mere market tailwind.

Strides Pharma Science Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 April 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 12 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Strides Pharma Science Ltd has seen a marked improvement in its valuation metrics, shifting from an attractive to a very attractive rating, even as the broader pharmaceuticals sector faces headwinds. With a current price-to-earnings (P/E) ratio of 15.56 and a price-to-book value (P/BV) of 2.90, the company stands out favourably against its peers, signalling a potential opportunity for investors seeking value in a challenging market environment.

Strides Pharma Science Ltd has recently exhibited a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend. Despite a day’s decline of 1.73%, the stock’s technical indicators reveal a complex interplay of bullish and bearish signals, suggesting a nuanced outlook for investors in this small-cap pharmaceutical player.

Strides Pharma Science Ltd has experienced a nuanced shift in its technical momentum, transitioning from a bullish to a mildly bullish trend as of early June 2026. While key weekly and monthly indicators such as MACD remain positive, bearish signals from RSI and mixed readings from other oscillators suggest a complex near-term outlook for this small-cap pharmaceutical player.

Strides Pharma Science Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Strides Pharma Science Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Strides Pharma Science Ltd experienced significant intraday weakness on 19 May 2026, with its stock price touching a low of Rs 1,045.8, marking a decline of 9.09% from the previous close. The stock underperformed its sector and broader market indices amid heightened volatility and persistent selling pressure.

Strides Pharma Science Ltd has demonstrated a commendable financial performance in the quarter ended March 2026, marking a positive shift in its financial trend. The company reported record-high net sales and operating profits, alongside a significant 27.1% growth in net profit after tax, signalling a strengthening position within the Pharmaceuticals & Biotechnology sector.

Strides Pharma Science Ltd., a mid-tier pharmaceutical manufacturer with a market capitalisation of ₹10,503 crores, delivered a strong fourth quarter performance for FY26, reporting consolidated net profit of ₹126.94 crores—a sequential decline of 37.19% from Q3 FY26's exceptional ₹202.11 crores, but a robust 54.45% year-on-year surge from Q4 FY25's ₹82.19 crores. The stock, trading at ₹1,150.35, has delivered remarkable returns of 74.30% over the past year, significantly outperforming both the Sensex and the pharmaceuticals sector.

Surging past its previous peaks, Strides Pharma Science Ltd touched a new 52-week high of Rs 1180.45 on 12 May 2026, marking a remarkable 82.62% gain over the past year. This rally stands in stark contrast to the broader market’s subdued performance, with the Sensex down 8.71% over the same period.

Surging past Rs 1174.7 on 11 May 2026, Strides Pharma Science Ltd has marked a significant milestone by reaching a fresh 52-week high. This achievement caps an impressive rally of 82.66% over the past year, vastly outperforming the Sensex, which declined by 3.86% in the same period.

Strides Pharma Science Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Surging to a fresh 52-week high of Rs 1174 on 8 May 2026, Strides Pharma Science Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a subdued Sensex. The stock’s recent rally, marked by a four-day consecutive gain and an 11.9% return in that span, underscores a strong technical alignment that has propelled it well above key moving averages.